WO2003027321A3 - Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine - Google Patents

Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine Download PDF

Info

Publication number
WO2003027321A3
WO2003027321A3 PCT/IB2002/004158 IB0204158W WO03027321A3 WO 2003027321 A3 WO2003027321 A3 WO 2003027321A3 IB 0204158 W IB0204158 W IB 0204158W WO 03027321 A3 WO03027321 A3 WO 03027321A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurogranin
diagnosis
treatment
methods
diseases associated
Prior art date
Application number
PCT/IB2002/004158
Other languages
English (en)
Other versions
WO2003027321A2 (fr
Inventor
Finn Skou Pedersen
Annette Balle Soerensen
Anne Ahlmann Nielsen
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Soerensen
Anne Ahlmann Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Soerensen, Anne Ahlmann Nielsen filed Critical Univ Aarhus
Priority to AU2002330713A priority Critical patent/AU2002330713A1/en
Publication of WO2003027321A2 publication Critical patent/WO2003027321A2/fr
Publication of WO2003027321A3 publication Critical patent/WO2003027321A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouvelles compositions et méthodes associées à la neurogranine, destinées à être utilisées pour le diagnostic et le traitement des lymphomes et de la leucémie. L'invention concerne en outre l'utilisation desdites nouvelles compositions pour des méthodes de criblage.
PCT/IB2002/004158 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine WO2003027321A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002330713A AU2002330713A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/962,916 2001-09-24
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,854 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/963,131 2001-09-24
US09/962,855 2001-09-24
US09/962,929 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Publications (2)

Publication Number Publication Date
WO2003027321A2 WO2003027321A2 (fr) 2003-04-03
WO2003027321A3 true WO2003027321A3 (fr) 2003-11-06

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1

Country Status (2)

Country Link
AU (4) AU2002364889A1 (fr)
WO (5) WO2003027321A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959969A2 (fr) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
KR20090019767A (ko) * 2006-02-14 2009-02-25 더프레지던트앤드펠로우즈오브하바드칼리지 유사분열 진행 유전자 및 유사분열을 조절하는 방법

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
WO2000037483A1 (fr) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Interactions proteine-proteine dans les troubles neurodegeneratifs
WO2001030973A2 (fr) * 1999-10-25 2001-05-03 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
WO2001034633A2 (fr) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methodes de traitement de la forme humaine de la maladie de huntington et methodes de criblage d'agents actifs
WO2001051670A2 (fr) * 2000-01-07 2001-07-19 Curagen Corporation Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
WO2002059367A2 (fr) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Jeu de microechantillons de diagnostic pour ibd, maladie de crohn et colite ulcereuse
WO2003025138A2 (fr) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
WO1997003358A1 (fr) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede pour identifier des inhibiteurs de la voie de transduction de signaux jak-stat
WO1998016557A1 (fr) * 1996-10-11 1998-04-23 The General Hospital Corporation Dosages pour recepteurs lies a la proteine g
JP2000506396A (ja) * 1996-11-01 2000-05-30 オニックス ファーマシューティカルズ，インコーポレイティド ホスファチジルイノシトール―３′―キナーゼ関連タンパク質をコードするヌクレオチド配列及びその利用
AU742342B2 (en) * 1997-05-21 2001-12-20 Clontech Laboratories, Inc. Nucleic acid arrays
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP1063887A1 (fr) * 1998-02-23 2001-01-03 Quark Biotech, Inc. Secretion de facteurs inhibiteurs de croissance dependant de p53
DE19817947A1 (de) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Myometrium-Tumorgewebe
IL139080A0 (en) * 1998-04-17 2001-11-25 Parker Hughes Inst Btx inhibitors and methods for their indentification and use
WO1999065928A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
GB2375172A (en) * 2000-02-07 2002-11-06 Quark Biotech Inc Fas pathway genes
DE60144277D1 (de) * 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
KR100830859B1 (ko) * 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
WO2001096390A2 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
JP2004527218A (ja) * 2000-09-08 2004-09-09 ニューヨーク・ユニバーシティ 紫外線応答性皮膚損傷の検出に有用な遺伝子マーカー
EP1362122A2 (fr) * 2000-09-12 2003-11-19 TransGenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription
AU2001290965A1 (en) * 2000-09-13 2002-03-26 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2002040637A2 (fr) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de pi3k p85
CA2436487A1 (fr) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Procedes d'inhibition de kinases
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
US20020137086A1 (en) * 2001-03-01 2002-09-26 Alexander Olek Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
WO2000037483A1 (fr) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Interactions proteine-proteine dans les troubles neurodegeneratifs
WO2001030973A2 (fr) * 1999-10-25 2001-05-03 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
WO2001034633A2 (fr) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methodes de traitement de la forme humaine de la maladie de huntington et methodes de criblage d'agents actifs
WO2001051670A2 (fr) * 2000-01-07 2001-07-19 Curagen Corporation Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
WO2002059367A2 (fr) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Jeu de microechantillons de diagnostic pour ibd, maladie de crohn et colite ulcereuse
WO2003025138A2 (fr) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 9 March 2001 (2001-03-09), XP002250336, retrieved from EBI accession no. EM_HUM:BC002835 Database accession no. BC002835 *
MARTINEZ DE ARRIETA CRUZ ET AL: "Structure, organization, and chromosomal mapping of the human neurogranin gene (NRGN).", GENOMICS, vol. 41, no. 2, 1997, pages 243 - 249, XP002250334, ISSN: 0888-7543 *
PAK JHANG HO ET AL: "Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: A study with knockout mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 21, 10 October 2000 (2000-10-10), October 10, 2000, pages 11232 - 11237, XP002250333, ISSN: 0027-8424 *
SVAREN JOHN ET AL: "EGR1 target genes in prostate carcinoma cells identified by microarray analysis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 49, 8 December 2000 (2000-12-08), pages 38524 - 38531, XP002250335, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2003027320A3 (fr) 2003-10-23
AU2002364889A1 (en) 2003-06-10
WO2003027295A2 (fr) 2003-04-03
AU2002330713A1 (en) 2003-04-07
AU2002337442A1 (en) 2003-04-07
WO2003043565A3 (fr) 2003-11-13
WO2003027276A2 (fr) 2003-04-03
AU2002364889A8 (en) 2003-06-10
WO2003027321A2 (fr) 2003-04-03
WO2003043565A2 (fr) 2003-05-30
WO2003027320A2 (fr) 2003-04-03
WO2003027276A3 (fr) 2004-02-12
WO2003027295A3 (fr) 2003-10-16
AU2002329000A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
WO2004084453A3 (fr) Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
GB0111186D0 (en) Novel compounds
WO2004080391A3 (fr) Nouveaux agents antibacteriens
WO2003045230A3 (fr) Compositions et procedes contre le cancer
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2004087073A3 (fr) Traitement d'etats de demyelinisation
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2003045324A3 (fr) 14-methyl-epothilones
CA2436572A1 (fr) Perylenequinones utilisees comme photosensibilisants et sonosensibilisants
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2004024077A3 (fr) Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
WO2003039484A3 (fr) Nouvelles compositions et methodes pour le traitement du cancer
WO2003071933A3 (fr) Nouvelles compositions et procedes de traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP